BioConscious Technologies Inc.
Founded 2015 · 5 employees on LinkedIn · 1 known investors
Endobits is clinical decision-support software that runs on top of FDA-cleared continuous glucose monitors to help qualified healthcare professionals and clinics manage glucose-related conditions such as dysglycemia and pre-diabetes. The software supports clinician-directed care and references CPT codes for billing, while providers retain full clinical authority.
Also known as Diabits · Endobits
Investors · 1
Company profile
researched Aug 2026BioConscious Technologies Inc., operating the Endobits platform at diabits.com, develops decision-support software for diabetes and broader metabolic care. The platform ingests continuous glucose monitoring (CGM), wearable, EMR and EHR data and translates it into prioritized clinical signals intended to identify which patients need attention and why. The company positions the offering under the label "Prevention as a Service" and also references a Virtual Clinic offering.
Endobits is presented for four distinct audiences: individuals seeking to check their glucose or assess metabolic risk; primary care practices looking to close gaps in care between patient visits; endocrinology practices where the software is meant to extend the capacity of certified diabetes care and education specialist (CDCES) teams; and payers and HMOs interested in preventing downstream diabetes complications. The company describes the platform as clinically validated.
A separate program, Moms+, studies how glucose patterns during pregnancy relate to a child's long-term metabolic health. Moms+ is described as not yet open for enrollment, with a mailing list collecting interest from pregnant people, those planning pregnancy, new mothers, clinicians and researchers, and with initial availability planned for California.
Business model
The company provides software rather than devices, operating on top of third-party continuous glucose monitors and clinical record systems. It targets both clinical organizations (primary care, endocrinology) and risk-bearing entities (payers and HMOs), alongside a direct-to-individual glucose-check entry point and a Virtual Clinic offering.
Latest developments
The Moms+ program, focused on glucose patterns in pregnancy and their relationship to a child's long-term metabolic health, is announced as forthcoming with initial availability in California and is collecting sign-ups ahead of enrollment.
▸Full profile — technology, go-to-market, geography
Technology
The platform aggregates and analyzes data from continuous glucose monitors, wearables, and electronic medical and health record systems to surface patients needing intervention. Stated ecosystem integrations and affiliations include CGM manufacturers Dexcom, Abbott and Senseonics; EMR/EHR and practice systems eClinicalWorks, Cerner, Athenahealth, OSCAR and Cliniko; HIPAA compliance; OpenAI; NVIDIA Inception; and the ADA.
Go-to-market
Segmented web-based positioning with distinct entry points for individuals, primary care, endocrinology, and payers/HMOs, plus an email waitlist to build demand for the forthcoming Moms+ program.
Individuals concerned about their metabolism or diabetes, primary care practices, endocrinology practices and their CDCES teams, and payers and health maintenance organizations.
Geography
Marketing indicates a North American focus, with the Moms+ program planned to launch first in California and interest-list options for other US states, Canada and other locations.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 1
launches, deals, and filingsThe company announced Moms+, a program studying how glucose patterns in pregnancy shape a child's long-term metabolic health, with enrollment to open in California first and a mailing list collecting early interest.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- BioConscious Technologies Inc.diabits.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does BioConscious Technologies Inc. do?
- Endobits is a metabolic and diabetes decision-support platform that turns CGM, wearable and EMR/EHR data into clinical action.
- Who are BioConscious Technologies Inc.'s investors?
- BioConscious Technologies Inc.'s investors include WUTIF Capital.